معرفی
Leena Hanski is a Senior University Lecturer in the Department of Pharmaceutical Biosciences at the Faculty of Pharmacy, University of Helsinki. She holds a Docentship in Pharmaceutical Biology from Åbo Akademi University (2013) and earned her PhD from the University of Helsinki Faculty of Pharmacy (2010). She is affiliated with the Institute of Sustainability Science (HELSUS), Helsinki One Health (HOH), and serves as a supervisor in the Doctoral Programme in Drug Research.
Her research spans multiple disciplines including pharmacy, microbiology, and virology, with specific focus on anti-infectives research, Chlamydia pneumoniae pathogenesis, sustainable health education, and pharmaceutical residues in the environment. Her work demonstrates strong interdisciplinary connections between pharmaceutical sciences, microbiology, and sustainability.
Analysis of her recent publications (2023-2025) reveals three major research strands: 1) Microbial pathogenesis focusing on Chlamydia pneumoniae and host-pathogen interactions; 2) Development of novel antibacterial compounds including etrasimod derivatives; and 3) Educational approaches for sustainable health transformation. Her work often bridges basic science with practical applications in drug development and environmental health.
Scientific Awards:
- Best International Teacher in University of Helsinki (2022)
- Innoopeli Prize 2022 (2022)
- Young Researcher Award (2014)
Dr. Hanski actively supervises doctoral students and master's theses, including María Pilar Cebollada Samper and Sara Buonocuore. She leads multiple significant research projects including 'Kasvien kestävä käyttö taistelussa infektiosairauksia vastaan' (2023-2026), 'Evaluating the Prevalence and Characteristics of Chlamydia pneumoniae' (2023-2027), and 'CHLAM-PROBES: Chemical biology for Chlamydia pneumoniae chemosensitization' (2019-present). She also contributes to educational innovation through the CELLS project focused on advancing learning and teaching in life sciences.
Her research team operates at the intersection of pharmaceutical biosciences, microbiology, and sustainability, with strong connections to the Helsinki One Health initiative and the Institute of Sustainability Science. The team investigates bacterial pathogenesis mechanisms while developing novel approaches for antimicrobial therapy and sustainable health education.
